ideSHi
institute for developing Science & Health initiatives

APPROVAL LETTER
IRB of ideSHi
PNR-25003

18 November 2025

Dr Rofiqur Rahman
Principal Investigator of research protocol # PNR-25003
Chief Operating Officer
Institute for developing Science and Health initiatives (ideSHi)

Subject: Approval of research protocol # PNR-25003

Approval Date:	**18 November 2025**
Expiration Date:	**19 November 2026**
Review Type:	Full Committee Review
Risk Level:	No more than minimal
Project type:	New Project

Dear Dr Rahman,

Thank you for your memo dated 13 November 2025 attaching the modified version of your research protocol # PNR-25003, titled "Assessing the awareness and evaluate the parental acceptance of typhoid conjugate vaccine for children aged 9 months to 14 years in urban slum area of Dhaka city corporations, Bangladesh", addressing the issues raised by the Institutional Review Board (IRB) in its 20th meeting held on 29th October 2025 at the ideSHi Meeting Room, and presenting the revised protocol to the IRB in its 21st Meeting held on 18th November 2025. After review and discussions on the revised protocol the committee unanimously accepted it. I am pleased to inform you that your protocol is **approved**. You will be required to observe the following terms and conditions in implementing the research protocol:

1) The research protocol is approved for a 12-month period from the date of approval of the protocol by the Institutional Review Board (IRB). The International IRB regulations require a review of an approved study not less than once per 12-month period. To comply with International IRB regulations, a continuing review application must be submitted to the IRB of ideSHi for this study to continue beyond **19 November 2026**.

   Protocol related to all necessary materials for continuing review must be submitted with sufficient time for review and issuing continued approval before the expiration date. Failure to initiate a continuing review application in a timely fashion may result in discontinuation of study activities until approval can be renewed. Performing study activities, including data analysis, beyond the expiration date results in noncompliance with International IRB regulations.

2) If the protocol is not started, the IRB approval will automatically be revoked after one year. After one year, you must seek the IRB's approval for revalidation of the protocol before initiating study activities.

3) As Principal Investigator, the ultimate responsibility for scientific and ethical conduct including the protection of the rights and welfare of study participants vests upon you. You shall also be responsible for ensuring competence, integrity, and ethical conduct of other investigators and staff directly involved in this research protocol.

4) You shall conduct the study in accordance with the IRB-approved protocol and shall fully comply with any subsequent determinations by the IRB.

5) You shall obtain prior approval from the IRB for any modification in the approved research protocol, study tools, and/or approved consent form(s), except in case of emergency to safeguard/eliminate apparent immediate hazards to study participants. Such changes must immediately be reported to the IRB.

6) You shall recruit/enroll participants for this study strictly adhering to the criteria mentioned in the research protocol.

7) You shall obtain legally effective informed consent (i.e. consent should be free from coercion or undue influence) from the selected study participants or their legally responsible representative/guardian, as approved in the protocol, using the approved consent form prior to their enrolment in this study. Before obtaining consent, all prospective study participants must be adequately informed about the purpose(s) of the study, its methods and procedures, and what would be done if they agree and also if they do not agree to participate in the study.

8) The participants must be informed that their participation in the study is voluntary and that they can withdraw their participation any time without any prejudice. Signed consent forms should be preserved for a period of at least **three years** following the official termination of the study.

9) You shall promptly report the occurrence of any Serious Adverse Event or unanticipated problems of potential risk to study participants or others to the IRB in writing within 24 hours of such occurrences.

10) Any significant new findings, developing during the course of this study that might affect the risks and benefits and thus influence either participation in the study or continuation of participation should be reported in writing to the participants and the IRB.

11) Data and/or samples should be collected and interviews should be conducted, asspecified in the IRB-approved protocol, and confidentiality must be maintained. Data/samples must be protected by reasonable security, safeguarding against risks suchas their loss or unauthorized access, destructions, used by others, and modification or disclosure of data. Data/samples should not be disclosed, made available to or use for purposes other than those specified in the protocol, and shall be preserved for a period, as specified under ideSHi policy.

12) You shall promptly and fully comply with the decision of the IRB to suspend or withdraw its approval for the research protocol.

13) The IRB should be immediately notified if the protocol is discontinued before theexpected date of completion.

14) You are responsible for systematic storage and retention of the original data pertaining to the research protocol, and the ownership of data after a certain period shall be determined as per the Institution's rules and regulations.

15) This approval is only valid whilst you hold a position at ideSHi; and in the event of your departure from the institute, a new Principal Investigator will be designated for the research protocol.

The IRB of ideSHi shall take into account the regulations of the Bangladesh Medical Research Council (BMRC), WHO, international guidelines for biomedical research as laid down by the Council of International Organization of Medical Sciences (CIOMS), the Declaration of Helsinki in relation to biomedical research involving human participants, ICH Guidelines on Good Clinical Practice (GCP), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Division of Microbiology and Infectious Diseases (DMID). If there is any new declaration involving human participants, the contents of such declaration should be appropriately adhered to, and the applicable laws and policies of the local government.

The IRB of ideSHi is comprised of 13 members. According to the IRB SOP, just majority (51%) is mandatory to make the quorum. The members who attended the above-mentioned meeting where your proposal was discussed are listed below:

1. Dr. S M Shamsuzzaman (Chair)
2. Dr. Fahima Chowdhury (Co-Chair)
3. Mr. MA Salam Khan (Member-Secretary)
4. Dr. Taufiqur Rahman Bhuiyan
5. Dr. Farhana Khanam (On Line)
6. Dr. Md. Shafiqul Islam (On-Line)
7. Mr. Nirod Chandra Saha (On Line)
8. Dr. Rosy Sultana
9. Dr. Noorjahan Begum Maliha (On Line)
10. Dr. Muhammad Mahbubur Rahman
11. Dr. Sharmin Jahan
12. Dr. Rofiqur Rahman



I wish you success in conducting the study.

Thank you.

M A Salam Khan
Member-Secretary

Cc: - Chairperson, IRB
- Lead, ideSHi.